We are putting together cohorts of well-annotated clinical samples across myeloid neoplasms that have been molecularly profiled using extensive genome profiling platforms (exomes, 100 gene plus gene panels) to conduct an agnostic meta-analysis of the molecular phylogenies across myeloid malignancies with the purpose to inform future diagnostic protocols. These include cohorts with MDS, MPN, AML, secondary AML, aplastic anemia, and  CMML.